Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - Priority Announcement: HIV/AIDS and STBBI

University of Toronto

$100,000.00

Combinatorial Design of Multiplexed mRNA Vaccines for HIV Broadly Neutralizing Antibody Induction

EF 2022-23

Résumé
In 2018, over sixty thousand people were predicted to be living with HIV in Canada. HIV remains a global pandemic with no effective vaccine. Broadly neutralizing antibodies (bNAbs) have been shown to inhibit most HIV strains from infecting human cells, but are difficult to induce. Attempts to develop a human bnAb vaccine candidate have so far failed. This is, in part, because the affinity maturation process of bnAbs is complex, and current vaccine candidates have struggled to deliver the appropriate signals to the immune system, in the correct order, to induce bnAbs in vivo. A large body of evidence supports our belief that a successful HIV vaccine must address three key parameters in parallel; 1) antigen design, 2) kinetics of antigen delivery and 3) stimulation of the immune system at the germinal center. Here, we propose to engineer an mRNA vaccine that can address and integrate each of these parameters. Previously, we have developed lipid nanoparticle (LNP) delivery systems that can not only facilitate extended protein expression of mRNA in lymph nodes, but also stimulate antigen-presenting cell maturation, antigen presentation in lymph nodes, and increase desirable antigen-specific CD4+/CD8+ responses. We believe that these dual delivery/adjuvant lipids could be repurposed to deliver effective HIV antigens to lymph nodes and program the host immune system to express bnAb antibodies against HIV. Our vaccine strategy facilitates multi-level control of immunogenicity through 1) optimization of mRNA expression and immunogenicity 2) development of potent dual delivery/adjuvant LNP formulations, and 3) optimization of kinetics and dosing for HIV mRNA vaccines. The ultimate goal of this proposal is to generate an effective HIV bnAb mRNA vaccine candidate.
Programme
Project Grant - Priority Announcement: HIV/AIDS and STBBI
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
472739
Name
Li Bowen
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
Combinatorial Design of Multiplexed mRNA Vaccines for HIV Broadly Neutralizing Antibody Induction
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: HIV/AIDS and STBBI
Keyworddelim
Biomaterials; Drug Delivery; Hiv Vaccine; Lipid Nanoparticles; Mrna Vaccine; Nonviral Gene Delivery
Abstract
In 2018, over sixty thousand people were predicted to be living with HIV in Canada. HIV remains a global pandemic with no effective vaccine. Broadly neutralizing antibodies (bNAbs) have been shown to inhibit most HIV strains from infecting human cells, but are difficult to induce. Attempts to develop a human bnAb vaccine candidate have so far failed. This is, in part, because the affinity maturation process of bnAbs is complex, and current vaccine candidates have struggled to deliver the appropriate signals to the immune system, in the correct order, to induce bnAbs in vivo. A large body of evidence supports our belief that a successful HIV vaccine must address three key parameters in parallel; 1) antigen design, 2) kinetics of antigen delivery and 3) stimulation of the immune system at the germinal center. Here, we propose to engineer an mRNA vaccine that can address and integrate each of these parameters. Previously, we have developed lipid nanoparticle (LNP) delivery systems that can not only facilitate extended protein expression of mRNA in lymph nodes, but also stimulate antigen-presenting cell maturation, antigen presentation in lymph nodes, and increase desirable antigen-specific CD4+/CD8+ responses. We believe that these dual delivery/adjuvant lipids could be repurposed to deliver effective HIV antigens to lymph nodes and program the host immune system to express bnAb antibodies against HIV. Our vaccine strategy facilitates multi-level control of immunogenicity through 1) optimization of mRNA expression and immunogenicity 2) development of potent dual delivery/adjuvant LNP formulations, and 3) optimization of kinetics and dosing for HIV mRNA vaccines. The ultimate goal of this proposal is to generate an effective HIV bnAb mRNA vaccine candidate.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Li, Bowen
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~